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Original ArticleCRISPR-Cas9 Gene Editing
of Hematopoietic Stem Cells
from Patients with Friedreich’s Ataxia
Celine J. Rocca,1 Joseph N. Rainaldi,1 Jay Sharma,1 Yanmeng Shi,1 Joseph H. Haquang,1 Jens Luebeck,2
Prashant Mali,2 and Stephanie Cherqui1
1Division of Genetics, Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA; 2Department of Bioengineering, University of California, San
Diego, La Jolla, CA 92093, USAFriedreich’s ataxia (FRDA) is an autosomal recessive neurode-
generative disorder caused by expansion of GAA repeats in
intron 1 of the frataxin (FXN) gene, leading to significant
decreased expression of frataxin, a mitochondrial iron-binding
protein. We previously reported that syngeneic hematopoietic
stem and progenitor cell (HSPC) transplantation prevented
neurodegeneration in the FRDA mouse model YG8R. We
showed that the mechanism of rescue was mediated by the
transfer of the functional frataxin from HSPC-derived micro-
glia/macrophage cells to neurons/myocytes. In this study, we
report the first step toward an autologous HSPC transplanta-
tion using the CRISPR-Cas9 system for FRDA. We first identi-
fied a pair of CRISPR RNAs (crRNAs) that efficiently removes
the GAA expansions in human FRDA lymphoblasts, restoring
the non-pathologic level of frataxin expression and normal-
izing mitochondrial activity. We also optimized the gene-edit-
ing approach in HSPCs isolated from healthy and FRDA pa-
tients’ peripheral blood and demonstrated normal
hematopoiesis of gene-edited cells in vitro and in vivo. The pro-
cedure did not induce cellular toxic effect or major off-target
events, but a p53-mediated cell proliferation delay was
observed in the gene-edited cells. This study provides the foun-
dation for the clinical translation of autologous transplanta-
tion of gene-corrected HSPCs for FRDA.Received 20 April 2020; accepted 27 April 2020;
https://doi.org/10.1016/j.omtm.2020.04.018.
Correspondence: Stephanie Cherqui, PhD, Division of Genetics, Department of
Pediatrics, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA
92093, USA.
E-mail: scherqui@ucsd.eduINTRODUCTION
Friedreich’s ataxia (FRDA) is an autosomal recessive genetic disorder
caused predominantly by a GAA expansion mutation in the first
intron of the gene encoding for the mitochondrial protein frataxin.1
This hyper-expansion leads to reduced expression of frataxin by
interfering with transcription initiation and elongation.2 Frataxin is
involved in iron homeostasis, and its reduction is associated with
mitochondrial iron accumulation, leading to oxidative stress.3 The
prevalence of FRDA is approximately 1 in 40,000 people with a typical
age of onset between 10 and 15 years. FRDA is a progressive, neuro-
degenerative movement disorder, often associated with cardiomyop-
athy and diabetes mellitus. FRDA’s pathogenesis is primarily caused
by degeneration of the sensory nerve fibers within dorsal root ganglia1026 Molecular Therapy: Methods & Clinical Development Vol. 17 June
This is an open access article under the CC BY-NC-ND license (ht(DRG), resulting in devolution of coordinated voluntary movement.
Ultimately patients require the use of a wheelchair for mobility.4
There is no effective treatment for FRDA.
We previously reported that transplantation of wild-type mouse he-
matopoietic stem and progenitor cells (HSPCs) into young mice that
recapitulate FRDA disease progression (YG8R)5 prevented coordina-
tion and locomotion deficits and vacuolar degeneration of the DRG
neurons as well as muscle weakness.6 We demonstrated that trans-
planted HSPCs migrated and engrafted abundantly in affected tissues
such as brain, spinal cord, DRG, heart, and skeletal muscle, where
they differentiated into microglial cells and macrophages. The mecha-
nism of rescue involves the transfer of the mitochondrial protein fra-
taxin from the HSPC-derived phagocytic cells to the neurons and my-
ocytes. These findings demonstrated for the first time the potential use
of HSPC transplantation for the treatment of FRDA. However, there
are significant risks associated with allogeneic HSPC transplantation;
immunosuppression and graft-versus-host disease are some of the
most prominent. Thus, the objective of this new study was to develop
an autologous HSPC transplantation approach for FRDA.
Frataxin expression has to be well regulated, downregulation leading
to the FRDA phenotype, and overexpression being associated with
toxicity.7,8 In addition, 95% of patients carry the GAA expansion in
the frataxin (FXN) gene intron 1 locus as the causative mutation.
Therefore, removing the hyper-expansion seems the optimal
approach as a gene correction strategy for FRDA. Targeted gene
correction using artificial endonucleases, such as zinc finger nucleases
(ZFNs), transcription activator-like effector nucleases (TALENs), and
RNA-guided nucleases CRISPR (clustered regularly interspaced short
palindromic repeat)-Cas9 (CRISPR-associated 9), brings the possibil-
ity of gene targeting to the forefront for clinical application.9 Removal2020 ª 2020 The Author(s).
tp://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Validation of CRISPR-Cas9-Mediated Gene Editing at the FXN Intron 1 Locus in Human FRDA Fibroblasts
(A) List of the best six crRNAs designed following the rule set 2 surrounding the FXN intron 1 GAA expansion. (B) Position of the crRNAs and regulatory elements surrounding
the FXN intron 1 GAA expansion. E-box, enhancer box; mt-binding site, microtubule-binding site. (C) Agarose gel showing the long-range PCR amplification of the region of
the FXN intron 1 containing the GAA expansion after gene editing with different pairs of crRNA precomplexed. Optimal gene-editing efficiency was found with the UP4/DN4
pair represented in line 5.
www.moleculartherapy.orgof the hyper-expansion for FRDA has previously been explored by
two groups using ZFNs or CRISPR-Cas9 in human FRDA lympho-
blasts and fibroblasts, as well as murine YG8R-derived fibroblasts.10,11
Both groups showed that excision of the GAA expansion within the
first intron of the frataxin gene is repaired by non-homologous end
joining (NHEJ) and leads to increased frataxin expression. Li
et al.10 also demonstrated an increase in aconitase activity and ATP
content in neuronal cells reprogrammed from corrected FRDA fibro-
blasts. However, the percentage of gene editing and FXN expression
was evaluated in clones derived from single cells, and the efficiency
was too low to be clinically relevant.
The objective of this study is to efficiently correct human FRDAHSPCs
with minimal manipulation to generate vehicles of functional frataxin
that will be delivered to diseased tissues. In our previous study, we
showed that 30% engraftment of donor wild-type (WT) HSPCs was
sufficient to prevent the development of the disease in the YG8Rmouse
model.6 In addition, because heterozygous individuals are asymptom-
atic, correcting one allele should recue the cellular phenotype. Finally,
introducing mutations by NHEJ-mediated repair within the intronic
sequence should have limited consequences to frataxin expression.MoleculaHerein, we report the use of the CRISPR-Cas9 system to remove the
expansion causing FRDA, thus restoring physiological expression of
frataxin in patients’ CD34+ cells. Additionally, we demonstrate that
despite a p53-dependant delay in cell proliferation, CRISPR-Cas9
double-strand breaks (DSBs) do not induce toxicity, and corrected
CD34+ cells were able to engraft and differentiate in immunodeficient
mice. This study represents an efficient and specific gene therapy
approach that will generate the cell product for a future ex vivo
HSPC gene therapy clinical trial for FRDA.
RESULTS
Optimization of CRISPR-Cas9-MediatedGeneEditing at the FXN
Intron 1 Locus in FRDA Fibroblasts and Lymphoblasts
Six guide CRISPR RNAs (crRNAs) were designed following rule set 2
(RS2)12 to remove the GAA expansion within the first intron of the
frataxin gene (Figure 1A) and tested in FRDA fibroblasts. Three
days post-transfection with different combinations of pre-assembled
ribonucleoprotein (RNP) complex long-range PCR was performed to
amplify the region containing GAA repeats (5 kb). The UP4/DN4
guide pair (4RNP) displayed the greatest gene-editing efficiency
excising an 2-kb DNA fragment containing the expansion (Figuresr Therapy: Methods & Clinical Development Vol. 17 June 2020 1027
Figure 2. GAA Gene-Editing Optimization in Human FRDA Lymphoblasts Using the UP4/DN4 cRNA Pair
(A) Schematic representing the ddPCR strategy to determine GAA gene-editing efficiency from genomic DNA. Red primers can only amplify the intronic region when GAA
gene editing occurs. (B) GAA gene-editing percentage measured by ddPCR in three different FRDA lymphoblastic cell lines 3 weeks post-electroporation with 4RNP or
4RNPenh. Data are means ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0005 (Student’s t test). (C) GAA gene-editing percentage measured by ddPCR in two different healthy
lymphoblastic cell lines 3 weeks post-electroporation with 4RNPenh. Data are means ± SEM. (D) Quantification of human frataxin mRNA in healthy and healthy/4RNPenh
lymphoblasts normalized to human TBP 3 weeks post-electroporation by ddPCR (n = 3). Data are means ± SEM. NS, not significant (Student’s t test). (E) Representative
western blot showing human frataxin protein expression in healthy and healthy/4RNPenh lymphoblasts 3 weeks post-electroporation. The bar graph represents the
quantification of human frataxin protein in healthy and healthy/4RNPenh lymphoblasts normalized to actin 3 weeks post-electroporation (n = 3). Data are means ± SEM. NS,
not significant (Student’s t test). (F) Quantification of human frataxin mRNA in healthy, carrier, FRDA, FRDA/4RNP, and FRDA/4RNPenh lymphoblasts 3 weeks post-
electroporation by ddPCR (n = 3). Data are represented as fold change relative to Healthy1 normalized to human TBP. Data are means ± SEM. *p < 0.05 (one-way ANOVA).
(G) Representative western blot showing human frataxin protein expression in Healthy1, Carrier1, FRDA1, FRDA1/4RNP, and FRDA1/4RNPenh lymphoblasts 3 weeks post-
electroporation. The bar graph represents the quantification of human frataxin protein in healthy, carrier, FRDA, FRDA/4RNP, and FRDA/4RNPenh lymphoblasts normalized
to actin 3 weeks post-electroporation (n = 3). Data are means ± SEM. *p < 0.05 (one-way ANOVA). (H) Mitochondrial activity measured in healthy, carrier, FRDA, and FRDA/
4RNPenh lymphoblasts in the presence of succinate. Data are means ± SEM. *p < 0.05, **p < 0.005, and ***p < 0.0005 (one-way ANOVA).
Molecular Therapy: Methods & Clinical Development1B and 1C). Sequencing of the 2-kb resected fragment confirmed
directed deletion of the repeats (Figure S1).
We then optimized the intronic repeat excision protocol using
4RNP and electroporation in non-adherent hematopoietic lympho-
blastic cell lines as a relevant model for CD34+ cells from healthy
donors, FRDA patients, and related carriers (Table S2), and in the
presence or absence of an electroporation enhancer (single-stranded1028 Molecular Therapy: Methods & Clinical Development Vol. 17 JuneDNA oligonucleotide designed in silico to possess no homology with
human, mouse, or rat genomes) to increase RNP uptake. We eval-
uated FXN editing efficiency by droplet digital PCR (ddPCR) using
reference primers at the 50 end of FXN intron 1 and experimental
primers flanking the expected deletion (Figure 2A). Gene-editing ef-
ficiency was twice as robust in the three patients’ cell lines when
electroporation of the 4RNP was performed in the presence of the
enhancer (39.8%–61.9% for FRDA/4RNPenh versus 17%–29.9%2020
Figure 3. Impact of GAA Gene Editing on FRDA
Lymphoblast Viability and Proliferative Capacity
(A) Percentage of live FRDA, FRDA/4RNP, and FRDA/
4RNPenh lymphoblasts over time post-electroporation (n =
3 for the three FRDA lymphoblastic cell lines). Data are
means ± SEM. *p < 0.05 and **p < 0.005 (one-way
ANOVA). (B) Fold expansion of FRDA, FRDA/4RNP, and
FRDA/4RNPenh lymphoblasts (n = 3 for the three FRDA
lymphoblastic cell lines) over time post-electroporation.
Data are means ± SEM. (C) Western blot representing the
time course expression of p53 and p21 after 4RNPenh
electroporation in FRDA lymphoblasts. (D) Western blot
representing the time course expression of p53 and p21
after RNP/control guide electroporation in FRDA lympho-
blasts.
www.moleculartherapy.orgfor FRDA/4RNP; Figure 2B, p < 0.05). These data represent an
optimal approach to remove the GAA hyperexpansion causing
FRDA.
CRISPR-Cas9-Mediated GAA Gene Editing Restores Frataxin
Expression and Mitochondrial Function in FRDA Lymphoblasts
Because regulatory elements are included in the excised DNA frag-
ment after 4RNP-mediated gene editing, we first ensured that normal
frataxin expression was maintained in modified healthy cells. Healthy
lymphoblasts with 60% of gene-editing efficiency (Figure 2C) had no
difference in FXN expression at both the mRNA and protein levels
(Figures 2D and 2E). In contrast, significant increases in frataxin
expression was seen at both the transcriptional and translational
levels in the three 4RNPenh-modified FRDA lymphoblast cell lines
compared to untreated cells (Figures 2F and 2G), leading to frataxin
expression comparable to the asymptomatic carrier and healthy cell
lines.
Biolog’s MitoPlate I-1 was utilized to assess mitochondrial function
by measuring the rates of electron flow into and through the electron
transport chain in response to metabolic substrates. First, the speci-
ficity of our assay was verified by measuring mitochondrial activity
in the presence of specific complex I, II, or III inhibitors in response
to succinate (Figure S2). We then quantified basal mitochondrial ac-
tivity in all of the cell lines without inhibitors. Results exhibit a defect
in electron flow rate for complex II/III in the FRDA cell lines (40%
less when compared to healthy cell lines). Removal of the hyper-
expansion was able to partially restore mitochondrial function in
the edited FRDA cells compared to the controls (Figure 2H). These
data suggest that our genetic-editing approach not only restores fra-
taxin expression but also improves cellular mitochondrial functions
in FRDA patient cells.Molecular Therapy: Methods &Gene Editing Triggers a p53-Mediated DNA
Damage Response That Delays Cell
Proliferation
To assess whether the GAA removal was
inducing any toxicity in the edited lymphoblastic
cell lines, proliferation rate and viability weredetermined during 7 days post-electroporation. A significant but
limited decrease in cell viability was observed at 24 and 48 h post-elec-
troporation in FRDA/4RNP and FRDA/4RNPenh compared to
FRDA control, with viability still greater than 75% (Figure 3A). How-
ever, proliferation was significantly impacted in both FRDA/4RNP
and FRDA/4RNPenh cells, exhibiting no proliferative activity during
the initial 24 h post-electroporation, resulting in lower number of
cells thereafter (Figure 3B).
A recent study reported that DSBs created by CRISPR-Cas9 led to a
transient p53-mediated DNA damage response, which delayed cell
proliferation.13 We confirmed that p53 and p21 expression were tran-
siently induced by 4RNPenh in FRDA lymphoblasts, with a peak at
24 h post-electroporation (Figure 3C). The same experiment carried
with a control crRNA did not affect p53/p21 expression, suggesting
that their overexpression is specifically due to DSBs (Figure 3D). To
demonstrate that p53 transient overexpression is not due to the disease
status of the FRDA cells, healthy lymphoblasts were also analyzed
showing that p53/p21were also transiently overexpressed (Figure S3A).
To emphasize the involvement of p53 in this delay, HL-60, a lympho-
blastic cell line characterized by a p53 deficiency,14 was similarly elec-
troporated with 4RNPenh (63.7% ± 3.1% GAA gene editing, data not
shown). No delay in proliferation was observed in gene-modified cells
compared to non-electroporated or Cas9-only control cells (Fig-
ure S3B). Finally, the FRDA GM15850 lymphoblastic cell line was
knocked down for p53 using a short hairpin RNA (shRNA) anti-p53
(Figure S3C, left) and subjected to 4RNPenh electroporation. This
new cell line exhibited the same proliferation profile as that of the con-
trol GM15850KD/Cas9, as opposed toGM15850/4RNPenh, which was
delayed compared to GM15850/Cas9 (Figure S3C, right). Taken
together, these data confirmed that the delay in cell growth observed
in the edited cells was due to p53 expression induced by DSBs.Clinical Development Vol. 17 June 2020 1029
Figure 4. GAA Gene Editing in Healthy CD34+ Cells and Consequence on Hematopoiesis Reconstitution Capacity
(A) GAA gene-editing percentage measured by ddPCR in four different healthy donors from two different sources (apheresis bags or fresh peripheral blood) 1 week post-
electroporation. (B) Percentage of live CD34+, CD34+/Cas9, and CD34+/4RNPenh cells over time post-electroporation (n = 4 for the three CD34+ cell lines). Data aremeans ±
SEM. *p < 0.05, **p < 0.005, and ***p < 0.0005 (one-way ANOVA). (C) Fold expansion of CD34+, CD34+/Cas9, and CD34+/4RNPenh cells (n = 4 for the three CD34+ cell lines)
over time post-electroporation. Data are means ± SEM. (D) Western blot representing the time course expression of p53 and p21 after 4RNPenh electroporation in CD34+
cells. (E) Colony-forming unit assay showing the percentages of the different colony types formed (n = 4). CFU-GEMM, CFU for granulocytes/erythroid cells/macrophages/
megakaryocytes; CFU-GM, CFU for granulocytes/macrophages; BFU-E, burst-forming units for erythroid cells; CFU-E, CFU for erythroid cells. Data are means ± SEM. Not
significant (one-way ANOVA). (F) GAA gene-editing percentage measured by ddPCR in each colony type for each healthy donor. (G) Human engraftment of gene-modified
CD34+ cells in peripheral blood of transplanted NSGmice 3months post-transplantation by flow cytometry (n = 10 for CD34+ and n = 10 for CD34+/4RNPenh), determined as
the percentage of human CD45+ cells of all human and murine CD45+ cells. Data are means ± SEM. Not significant (Student’s t test). (H) Lineage distribution of human cells
engrafted in NSGmice in the bone marrow 3months post-transplantation determined by flow cytometry using fluorescent-labeled antibodies to human T cells (CD3), human
B cells (CD19), and human myeloid cells (CD33+). Data are means ± SEM. Not significant (Student’s t test). (I) GAA gene-editing percentage measured by ddPCR in bone
marrow (BM), spleen, and thymus of transplanted NSG mice 3 months post-transplantation. Data are means ± SEM.
Molecular Therapy: Methods & Clinical DevelopmentOptimization and In Vitro and In Vivo Assessments of CRISPR-
Cas9-Mediated FXN GAA Excision in Peripheral Blood CD34+
Cells
We next optimized 4RNPenh-mediated gene editing in healthy hu-
man CD34+ HPSCs isolated from two different sources: frozen gran-
ulocyte colony-stimulating factor (G-CSF)-mobilized apheresis bags1030 Molecular Therapy: Methods & Clinical Development Vol. 17 Juneand fresh peripheral blood (Figure 4A). Gene editing efficiency in
apheresis and peripheral derived cells reached 32.6% and 49.8%,
respectively (Figure 4A). Cell viability of CD34+/4RNPenh was signif-
icantly lower at 48 and 96 h post-electroporation compared to CD34+
cells (CD34+) and Cas9-electroporated cells (CD34+/Cas9), but still
above 74% (Figure 4B). As expected, significant delay in cell2020
www.moleculartherapy.orgproliferation was observed in CD34+/4RNPenh compared to CD34+
and CD34+/Cas9 controls (Figure 4C), which was shown to be due to
p53 transient overexpression (Figures 4D; Figure S4).
The differentiation ability of individual CD34+ cells was verified using
colony-forming unit (CFU) assays showing that hematopoietic line-
age colony distribution in 4RNPenh-edited CD34+ cells was similar
to controls (Figure 4E). Heterogeneous rates of gene editing were
measured in each colony type for the different donor cells, illustrating
an unbiased distribution among the different hematopoietic cell lin-
eages: 10.6%–52.6% in CFU for granulocytes/erythroid cells/macro-
phages/megakaryocytes (CFU-GEMM), 6.4%–49% in CFU for gran-
ulocytes/macrophages (CFU-GM), 17.5%–58% in burst-forming
units for erythroid cells (BFU-E), and 2.8%–71.7% in CFU for
erythroid cells (CFU-E) (Figure 4F). A single colony analysis also
showed that all of the clones presented with a monoallelic GAA dele-
tion (Figure S5).
The repopulating capacity of edited CD34+ cells was also evaluated
in vivo through xenotransplantation in NSG mice. Control and
4RNPenh-edited CD34+ cells were transplanted into sub-lethally irra-
diated newborn NSG mice via intrahepatic injection. Engraftment
and hematopoiesis reconstitution assessments displayed substantial
numbers of human hematopoietic CD45+ cells in peripheral blood
of all transplanted mice in both groups (24.93% ± 7.461% in
CD34+ mice, and 27.99% ± 8.734% in CD34+/4RNPenh mice) (Fig-
ure 4G). Enumeration of T cells (CD3), B cells (CD19), and myeloid
progenitors (CD33) by flow cytometry showed comparable lineage
distribution in the bone marrow of both CD34+ and CD34+/
4RNPenh mice (Figure 4H). The input cells had a gene-editing rate
ranging from 24.3% to 49.8%, and at 3 months post-transplant,
gene editing ranged from 0.15% to 18% with a mean of 5.49% in
bone marrow, from 0.1% to 3.90% with a mean of 1.16% in spleen,
and from 0.2% to 15% with a mean of 4.65% in thymus (Figure 4I).
Overall, the data obtained from CD34+ cells demonstrated a high per-
centage of GAA repeat excision and normal hematopoietic lineage
differentiation capacity in vivo and in vitro.
FXN GAA Expansion Editing in Peripheral Blood CD34+ Cells
from FRDA Patients
Directed removal of FXN GAA expansion was then tested in CD34+
cells isolated from fresh peripheral blood collected from five FRDA
patients, with three healthy parents (carrier) and three healthy donors
used as controls (Table S3). Gene-repair rates of the input cells ranged
from 12.1% to 55.9%with a mean of 29.66% (Figure 5A). Cell viability
of 4RNPenh-edited FRDA CD34+ cells was significantly decreased at
6, 48, 72, and 96 h post-electroporation compared to controls, but it
was consistently more than 70% (Figure 5B). As expected, 4RNPenh-
edited FRDA CD34+ cells exhibited a delay in cell proliferation
(Figure 5C).
We then assessed frataxin transcriptional expression in the different
donor groups. An increase in FXN mRNA expression was observedMoleculain the edited cells from all of the patients with a mean expression
of 0.334 for FRDA cells versus 1.25 for FRDA/4RNPenh cells (Fig-
ure 5D). While this increase was not significant, there was a direct
correlation between the proportion of gene correction and level of
FXN expression (R2 = 0.73) (Figure 5E). A CFU assay demonstrated
colony lineages from FRDA/4RNPenh CD34+ cells comparable to
FDRA, healthy, and carrier CD34+ cell controls (Figure 5F). Gene-ed-
iting rates in the different colony lineages confirmed that CRISPR-
Cas9-mediated expansion removal was retained and unbiasedly
distributed within the different hematopoietic progeny (Figure 5G).
To investigate functional rescue using a limited number of cells, we
tested the expression of three mitochondrial (mt) complex subunit
genes mtDN6 (complex I), mtCO2 (complex II), and mtATP6 (com-
plex V), which were shown to be affected in whole-blood cells from
FRDA patients.15 A decrease of expression of these markers was
observed in FRDA CD34+ cells compared to healthy cells. An
increased expression of these markers was observed in gene-edited
FRDACD34+, cells although it did not reach significance (Figure 5H).
These data demonstrate that CRISPR-Cas9-mediated GAA excision
from the frataxin gene is feasible in the targeted CD34+ HSPCs
from FRDA patients, leading to an increase in FXN expression and
an improvement of mitochondrial biomarkers.
Assessment of Nuclease Specificity
The specificity of 4RNPenh-mediated gene editing was assessed in
FRDA CD34+ cells using in silico COSMID tool (https://crispr.bme.
gatech.edu).16 Results showed six potential off-target sites within
the following genes’ introns: AGAP1, UNC5D, LRP1B, RARB,
EPHX2, and DGKG (Table S4). Indel formation was tested via a T7
endonuclease 1 (T7E1) mismatch detection assay using guide DNA
(gDNA) isolated from the edited cells. No detectable off-target activ-
ity was found in these six regions for all of the patients (Figure S6). To
confirm this result, we also sequenced PCR products and compared
them to PCR amplicons from corresponding non-edited FRDA
CD34+ cells. Deconvolution analysis using the ICE Synthego software
(https://ice.synthego.com) exhibited no indel formation in any of the
edited gDNA compared to the non-edited gDNA (Table S5). Finally,
these same amplicons have been analyzed by next-generation
sequencing (NGS) for a more precise reading. For the six intronic
areas, more than 98.66% of reads were without indels (Figure S7).
Collectively, these data show that UP4 and DN4 crRNA are very spe-
cific to the target region of frataxin gene.
DISCUSSION
Herein, we report preliminary data for the preclinical study of tar-
geted gene editing of HSPCs for an autologous transplantation strat-
egy for FRDA by removing the GAA expansion in intron 1 of the fra-
taxin gene using CRIPSR-Cas9. The efficiency of gene repair in
CD34+ cells isolated from peripheral blood from FRDA patients
could reach 55%. We previously showed that a proportion of 30%
of the cell product usingWTHSPCs could rescue FRDA.6 In addition,
increased frataxin expression could be achieved in CD34+ cells iso-
lated from FRDA patients, as well as presence and stable rates ofr Therapy: Methods & Clinical Development Vol. 17 June 2020 1031
Figure 5. GAA Gene Editing in FRDA Patient CD34+
Cells and Impact on FXN Expression and
Hematopoiesis Reconstitution
(A) GAA gene-editing percentage measured by ddPCR in
five different FRDA patient donors from fresh peripheral
blood 1 week post-electroporation. (B) Viability of healthy,
carrier, FRDA, and FRDA/4RNPenh CD34+ cells over time
post-electroporation (n = 3 for healthy, n = 3 for carrier, n =
5 for FRDA, and n = 5 for FRDA/4RNPenh). Data are
means ± SEM. *p < 0.05 and **p < 0.005 (one-way
ANOVA). (C) Fold expansion of healthy, carrier, FRDA, and
FRDA/4RNPenh cells over time post-electroporation (n = 3
for healthy, n = 3 for carrier, n = 5 for FRDA, and n = 5 for
FRDA/4RNPenh). Data are means ± SEM. (D) Quantifica-
tion of human frataxin mRNA in healthy, carrier, FRDA, and
FRDA/4RNPenh CD34+ cells 1 week post-electroporation
by ddPCR (n = 3 for healthy, n = 3 for carrier, n = 5 for
FRDA, and n = 5 for FRDA/4RNPenh). Data are normalized
to human TBP. Data are means ± SEM. *p < 0.05 and **p <
0.05 (one-way ANOVA). (E) Correlation curve showing the
significant relationship between the percentage of GAA
gene editing and the increased expression of human fra-
taxin mRNA in gene-modified CD34+ cells from FRDA pa-
tient donors. (F) Colony-forming unit assay showing the
percentages of the different colony types formed (n = 3 for
healthy, n = 3 for carrier, n = 5 for FRDA, and n = 5 for
FRDA/4RNPenh). CFU-GEMM, CFU for granulocytes/
erythroid cells/macrophages/megakaryocytes; CFU-GM,
CFU for granulocytes/macrophages; BFU-E, burst-forming
units for erythroid cells); CFU-E, CFU for erythroid cells.
Data are means ± SEM. Not significant (one-way ANOVA).
(G) GAA gene-editing percentage measured by ddPCR in
each colony type for each FRDA donor. (H) Quantification of
the human mitochondrial (mt) complex subunit mRNA
mtDN6 (complex I), mtCO2 (complex II), and mtATP6
(complex V) by qRT-PCR in healthy, FRDA, and FRDA/
4RNPenh CD34+ cells 1 week post-electroporation. Data
are represented as fold change relative to healthy and
normalized to human tubulin. Data are means ± SEM. *p <
0.05 and **p < 0.005 (Student’s t test).
Molecular Therapy: Methods & Clinical Developmentgene editing in the hematopoietic progeny in vitro and in vivo, and no
off-target activity was detected in the final cell products. Thus, our
study supports the development of this potential therapeutic strategy
for FRDA. Recent results of ongoing clinical trials using CRISPR-
Cas9-mediated gene-edited HSPC therapy for transfusion-dependent
b-thalassemia and sickle cell disease support the efficacy and safety of
this approach.17
Optimization, safety, and efficacy of our targeted gene-editing
approach were obtained through a series of functional assays using
FRDA patients’ cell lines. Because of the presence of an mt-bind-1032 Molecular Therapy: Methods & Clinical Development Vol. 17 June 2020ing site and E-box regulation sequences only
98 bp upstream of the GAA repeats, excision
of the expansion made their removal inevitable.
Although these regulatory sequences are
known to contribute to the frataxin promoteractivity,18 their deletion did not impact frataxin expression in
healthy cells. This result confirms previous data obtained in
K562 cells.10 Initial optimization of RNP transfection via electro-
poration in patient-derived lymphoblasts showed that inclusion
of a carrier DNA enhancer dramatically increased the percentage
of gene-editing efficiency. This is the first demonstration that
this enhancer could increase targeted genome efficiency in
CD34+ cells, and validation of its use in clinical trials should be
the next critical step. Physiologic levels of frataxin, comparable
to those of carriers and healthy controls, were thus achieved,
both at the mRNA and protein levels.
www.moleculartherapy.orgDeficits of frataxin are associated with mitochondrial iron accumula-
tion, deficient Fe-S cluster biogenesis, increased sensitivity to oxida-
tive stress, and deficits in respiratory chain complex activity.19,20
However, FRDA patients’ blood cells do not exhibit major defects
in mitochondrial function.21 Hence, functional rescue was difficult
to demonstrate using lymphoblasts, and regular mitochondrial and
oxidative stress assays failed to show impairment. However, Biolog’s
MitoPlate I-1 assay, which is highly strenuous on the respiratory
chain pathway, revealed significant differences between healthy and
FRDA lymphoblasts. Partial functional rescue in gene-corrected
FRDA lymphoblasts was then demonstrated.
While our approach did not establish a deleterious cytotoxic effect,
it notably delayed cell proliferation during the first 48 h post-elec-
troporation. We confirmed that p53 overexpression, in response to
the presence of DNA DSBs, was responsible for this cell cycle
block.13 Indeed, the ribonuclease complex 4RNPenh generates
four potential DSBs to remove the GAA expansion in FXN, and
we showed overexpression of p53 at 24-h post-electroporation in
healthy and FRDA lymphoblasts as well as in CD34+ cells only
when electroporated with 4RNPenh but not with a crRNA control.
In contrast, cell proliferation was not affected in p53-knockout
HL60 lymphoblasts or FRDA lymphoblasts with p53 knockdown.
Because human CD34+ cells were transplanted in NSG mice only
24 h after electroporation, the p53-mediated proliferation delay
observed after 4RNPenh-mediated gene editing could explain the
drop of efficiency rate between the input cells and the in vivo
bone marrow cells. This reduction in gene-repair proportions
from in vitro to in vivo have been reported by other groups.22–26
Efforts to expand CD34+ cells in culture in an undifferentiated
state27 or using p53 inhibitors13 should help to significantly in-
crease gene-editing efficiency in vivo.
Among the five FRDA patients tested, gene-editing efficiency was var-
iable. Although size of the trinucleotide repeat expansion correlates
with the disease severity,28 we did not find any correlation between
expansion size and gene-editing efficiency. However, abnormal sec-
ondary DNA structures by long GAA tracts29–32 could presumably
be responsible for challenging the access of crRNA to the targeting
site and explain the different genome editing rates obtained in the
different patients’ lymphoblasts and CD34+ cells.
Our results support the use of the CRISPR-Cas9 to remove the GAA
expansion in FRDA patients’ CD34+ cells, leading to physiological
rescue of frataxin expression, when the percentage of gene editing
is sufficiently high, without cytotoxic effects in vitro or in vivo, and
maintaining HSPC engraftment ability and clonogenicity. This
work represents a step toward the clinical translation of autologous
transplantation of gene-corrected HSPCs for FRDA.
MATERIALS AND METHODS
Human Blood Cells
CD34+ HSPCs from healthy donors were obtained from two different
sources: leukapheresis bags of G-SCF-mobilized cells kindly providedMoleculaby Dr. J. Bui (University of California, San Diego), and 500 mL of
freshly withdrawn peripheral blood from the Scripps Research’s
Normal Blood Donor Service. For the study including FRDA patients,
up to 100 mL of peripheral blood was withdrawn from FRDA pa-
tients, carriers, or healthy donors after written informed consent un-
der Institutional Review Board-approved protocol #161762. The
conduct of these studies conformed to the Declaration of Helsinki
protocols and all US federal regulations required for the protection
of human subjects.Mouse Studies
Use of non-obese diabetic (NOD) severe combined immunodefi-
ciency (SCID) Il2rg/ (NSG) mice (Jackson Laboratory, Bar Harbor,
ME, USA) for xenotransplantation studies was approved by the Na-
tional Institute of Allergy and Infectious Diseases (NIAID) Institu-
tional Animal Care and Use Committee under protocol S14042.
The conduct of these studies conformed to Association for Assess-
ment and Accreditation of Laboratory Animal Care International
guidelines and all US federal regulations governing the protection
of research animals.RNP Protein Complex Assembly
Single Alt-R crRNA and Alt-R trans-activating crRNA (tracrRNA)
(100 mM, Integrated DNA Technologies, San Diego, CA, USA) oligo-
nucleotides were mixed at equimolar concentrations to a final con-
centration of 44 mM and complexed together at 95C for 5. The
Alt-R S.p. HiFi Cas9 nuclease V3 protein (62 mM, IDT, San Diego,
CA, USA) was diluted in electroporation buffer (buffer R, Invitrogen,
Carlsbad, CA, USA) or Opti-MEM to 36 mM. Equivalent volumes of
crRNA-tracrRNA and diluted HiFi Cas9 nuclease were mixed
together and incubated at room temperature for 10–20 min.Transfection
Human FRDA fibroblasts (GM03816) from the Coriell Institute were
cultured in Eagle’s minimal essential medium (EMEM)/15% fetal
bovine serum (FBS) at 37C, 5% CO2.. Transfection was carried out
using the Lipofectamine CRISPRMAX Cas9 transfection reagent kit
(Invitrogen, Carlsbad, CA, USA) following the manufacturer’s in-
structions. Briefly, RNP complex and CRISPRMAX reagent were
each diluted in 50 mL of Opti-MEM medium and mixed. The RNP
complex solution was then immediately added to the CRISPRMAX
reagent solution and mixed. After a 5- to 10-min incubation, the so-
lution was added to the cells.Long-Range PCR
At 72 h post-transfection, gDNA was isolated using QuickExtract
DNA extraction solution (Lucigen, Middleton, WI, USA) and PCR
was carried out using 10 ng of gDNA, 2 Super Master Mix (BioTool,
Houston, TX, USA), and primers listed in Table S1. The PCR pro-
gram was set up as follows: (94C for 20 s, 65.6C for 2 min 30 s)
 20, (94C for 20 s, 65.6C for 2 min 30 s + 15 s/cycle)  17.
PCR products were then run on a 0.7% agarose gel. Band intensity
was quantified using ImageJ.r Therapy: Methods & Clinical Development Vol. 17 June 2020 1033
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Human FRDA lymphoblasts from the Coriell Institute (Table S2)
were cultured in RPMI 1640/15% FBS at 37C, 5% CO2. 1 105 lym-
phoblasts were resuspended in 9 mL of electroporation buffer (buffer
R, Invitrogen, Carlsbad, CA, USA); 1 mL of RNP complex was added
as well as 1.8 mM Alt-R Cas9 electroporation enhancer (IDT, San
Diego, CA, USA) when required. 10 mL was then pipetted into the
10-mL Neon tip (Invitrogen, Carlsbad, CA, USA), and the cell/RNP
complex mixture was electroporated at 1,600 V, 10 ms, for three
pulses using the Neon electroporator (Invitrogen, Carlsbad, CA,
USA). Cells were immediately returned to pre-equilibrated cultured
media in 24-well plates. The same protocol and number of cells
were used for CD34+ HSPCs for in vitro experiments while 1  106
CD34+HSPCs (resuspended in 90 mL of buffer R) were electroporated
with 10 mL of RNP complex for transplantation in one NSG mouse.
ddPCR
gDNA from cells was isolated using QuickExtract (Lucigen, Middle-
ton, WI, USA) and from tissues using a DNeasy Blood & Tissue kit
(QIAGEN, Germantown, MD, USA). To measure GAA gene-editing
efficiency, 100 ng of gDNA, HindIII (NEB, Ipswich, MA, USA), and
1 ddPCR supermixes for probes (no dUTP [deoxyuridine triphos-
phate]) (Bio-Rad, Hercules, CA, USA) were used in combination
with two sets of primers/probes (Table S1) to generate the droplets us-
ing the QX200 droplet generator (Bio-Rad, Hercules, CA, USA).
Next, the droplets were transferred to a 96-well plate and the
following PCR was carried out: 95C for 10-min ramp at 2C/s,
(94C for 30-s ramp at 2C/s, 60C for 1-min ramp at 2C/s)  39,
98C for 10-min ramp at 2C/s. The 96-well plate was then read by
the QX200 Droplet reader (Bio-Rad, Hercules, CA, USA). For fra-
taxin expression, the protocol was similar but using cDNA and the
following sets of primers: human frataxin (Bio-Rad, Hercules, CA,
USA, #10031252) and human TBP (Bio-Rad, Hercules, CA, USA,
#10031255).
Western Blot
Proteins were isolated from lymphoblasts and transferred to a polyvi-
nylidene fluoride membrane as previously described.33 The following
antibodies were used: mouse anti-frataxin antibody (Abcam, Cam-
bridge, MA, USA, ab110328), mouse anti-p53 antibody (Santa Cruz
Biotechnology [SCBT], Santa Cruz, CA, USA, sc-126), mouse anti-
p21 antibody (SCBT, Santa Cruz, CA, USA, sc-6246), rabbit anti-
PAN actin antibody (Cell Signaling Technology, Danvers, MA,
USA, #4968S), and mouse anti-GAPDH antibody (SCBT, Santa
Cruz, CA, USA, sc-365062) followed by goat anti-mouse or anti-rab-
bit horseradish peroxidase-conjugated secondary antibodies. Signal
was revealed using the Azure 600 imager, and bands were quantified
using the AzureSpot analysis software (Azure Biosystems, Dublin,
CA, USA).
MitoPlate I-1
Mitochondrial activity within lymphoblasts was measured using the
MitoPlate I-1 (Biolog, Hayward, CA, USA, #14104) following the
manufacturer’s instructions. Briefly, wells containing the different1034 Molecular Therapy: Methods & Clinical Development Vol. 17 Junemitochondrial inhibitors were rehydrated with a solution containing
redox dye mix, saponin, and succinate for 1 h at 37C. Lymphoblasts
were washed with PBS (1) and resuspended at a density of 105 cells/
30 mL using 1 Biolog MAS (Biolog, Hayward, CA, USA) and added
to each well. The MitoPlate I-1 was then loaded into the OmniLog
PM-M system (Biolog, Hayward, CA, USA) for kinetic reading.
Lymphoblast p53 Knockdown
GM15850 lymphoblasts (600 viable cells/mL) were incubated over-
night with RPMI 1640/15% FBS, Polybrene (5 mg/mL), and p53
shRNA (h) lentivirus particles (SCBT, Santa Cruz, CA, USA, #sc-
29435-V) at an MOI of 10. On the next day, media were replaced
with RPMI 1640/15% FBS and cells were incubated during two nights.
Selection occurred through incubation of transduced cells with puro-
mycin concentrations of 0, 2, 5, and 10 mg/mL to produce stable cell
lines, which were analyzed for p53 knockdown via western blot.
CD34+ HSPC Isolation and In Vitro Differentiation
Peripheral blood was first diluted in PBS (1) and white blood cells
were separated from red blood cells and plasma using Ficoll, while
leukapheresis bags were directly thawed and diluted in Miltenyi
buffer. Then, CD34+ HSPCs were isolated using the Miltenyi Biotec
MACS human CD34 MicroBead kit (Miltenyi Biotec, San Diego,
CA, USA) following the manufacturer’s instructions. With 100 mL
of peripheral blood, an average of 1.5  106 CD34+ HSPCs were ob-
tained. Cells were cultured in complete medium consisting of Iscove’s
modified Dulbecco’s medium (IMDM) supplemented with FBS, BSA,
glutamine, penicillin/streptomycin, human interleukin (hIL)-3, hIL-
6, and human stem cell factor (h-SCF) (PeproTech, Rocky Hill, NJ,
USA) at 37C. Cell proliferation and viability were determined using
an automated cell counter (Bio-Rad, Hercules, CA, USA). CFU assays
were performed using MethoCult H4434 enriched methylcellulose
(STEMCELL Technologies, Cambridge, MA, USA). Two days after
electroporation, 3,000 cells from each condition were mixed with
3 mL of MethoCult and plated in triplicate into 35-mm gridded cell
culture dishes. After 12–14 days of culture at 37C, 5% CO2, the
different types of hematopoietic colonies were identified and counted.
CFU (15/type) were plucked for genomic DNA isolation using
QuickExtract (Lucigen, Middleton, WI, USA).
Allelic Deletion Detection
Single CD34+ colonies were isolated and individually placed in
QuickExtract (Lucigen, Middleton, WI, USA) for DNA isolation.
PCR was carried out using 25 ng of gDNA, PCR Master Mix (2)
(Thermo Fisher Scientific, West Columbia, SC, USA), 4% DMSO,
and primers listed in Table S1. The PCR program was set up as fol-
lows: (95C for 30 s, 56C for 30 s, and 72C for 1 min)  35. PCR
products were then run on a 1% agarose gel. Colony genotypes
were then binned based on positive bands into non-allelic, mono-
allelic, or bi-allelic deletion.
NSG Mouse Transplantation
The NOD SCID Il2rg/ (NSG) mice (Jackson Laboratory, Bar Har-
bor, ME, USA) were housed in a pathogen-free colony in a2020
www.moleculartherapy.orgbiocontainment vivarium and handled in laminar flow hoods.
Newborn pups at 3–7 days of life of both sexes were injected with
1  106 cells/pup via intrahepatic injection of unmodified or gene-
edited human CD34+ cells 1 day after conditioning with 1.25 Gy of
sub-lethal body irradiation from an X-ray energy irradiator, and al-
lowed to engraft during 12–16 weeks.34
Flow Cytometry Analysis of Hematopoiesis
Human engraftment in NSG mice was determined 2 months post-
transplantation from peripheral blood using a fluorescein isothiocya-
nate (FITC) anti-human CD45 (BioLegend, SanDiego, CA, USA) and
a phycoerythrin (PE) anti-mouse CD45 (BioLegend, San Diego, CA,
USA). Hematopoiesis reconstitution was determined at the time of
sacrifice, 12–16 weeks post-transplantation, from peripheral blood
using the following conjugated antibodies: allophycocyanin (APC)/
Cyanine7 anti-human CD19, FITC anti-human CD3, PE anti-human
CD33, and APC anti-human CD45 (BioLegend, San Diego, CA,
USA). All of the flow cytometric analyses were performed using the
BD LSRFortessa flow cytometer (BD Biosciences, San Jose, CA, USA).
qRT-PCR
Total RNA was prepared from lymphoblasts or CD34+ cells using an
RNeasy kit (QIAGEN, Germantown, MD, USA) according to the
manufacturer’s instructions. cDNA was then prepared using an iS-
cript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA), and primers
listed in Table S1 and SYBR Green master mix (Bio-Rad, Hercules,
CA, USA) were used following the manufacturer’s instructions.
Off-Target Assessment
Potential off-target regions were predicted using COSMID software.
An Alt-R genome editing detection kit (IDT, San Diego, CA, USA)
and primers listed in Table S1 were used to detect the presence of po-
tential indels within edited gDNA. Fragments were Sanger sequenced
and Amplicon-EZ next-generation sequenced by Genewiz (La Jolla,
CA, USA). Sanger chromatograms were compared to controls via
Synthego ICE deconvolution, and single-nucleotide polymorphisms
were detected from NGS.
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